MedTrace Logo

Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes

NCT01059799 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 435

Last updated 2017-03-30

Study results available
· View outcomes & findings →

Summary

This trial is conducted in Asia and Japan. The aim of this trial is to compare insulin degludec (NN1250) with insulin glargine both combined with oral antidiabetic drugs (OADs) in subjects with type 2 diabetes never treated with insulin.

Conditions

Interventions

DRUG

insulin degludec

Insulin degludec injected subcutaneously (under the skin) once daily. The doses will be individually adjusted

DRUG

insulin glargine

Insulin glargine injected subcutaneously (under the skin) once daily. The doses will be individually adjusted

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-01
Primary Completion
2010-12-16
Completion
2010-12-16

Countries

  • Hong Kong
  • Japan
  • Malaysia
  • South Korea
  • Taiwan
  • Thailand

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01059799 on ClinicalTrials.gov